Drugs like Ozempic show potential to help those with addiction with little downside risk. How quickly can their availability be expanded? Nicholas Reville of CASPR makes his case.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.